Form 4 for PRCT PROCEPT BioRobotics Corp
Accepted 2025-06-12 00:00:00 ET · period of report 2025-06-10 · accession 0001628280-25-031117 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2025-06-12 | 2025-06-10+ | PRCT | Desai Antal Rohit | Dir | S - Sale | $62.93 | -75.0K | 64.4K | -54% | -$4.72M |
| D | 2025-06-12 | 2025-06-10 | PRCT | Desai Antal Rohit | Dir | A - Grant | $0.00 | +1,538 | 8,403 | +22% | $0 |
| D | 2025-06-12 | 2025-06-10 | PRCT | Desai Antal Rohit | Dir | A - Grant | $0.00 | +2,771 | 2,771 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-10 | S | D | 4,862 | $63.23 | 84,501 | I By The 2:22 DNA Trust | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.56 to $63.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 2 | Common | Common Stock | 2025-06-12 | S | D | 5,049 | $62.33 | 14,363 | I | — | — | (F10) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.89 to $62.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 3 | Common | Common Stock | 2025-06-12 | S | D | 19,951 | $61.28 | 19,412 | I By The 2:22 DNA Trust | — | — | (F9) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.89 to $61.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 4 | Common | Common Stock | 2025-06-11 | S | D | 5,717 | $64.27 | 39,363 | I By The 2:22 DNA Trust | — | — | (F8) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.08 to $64.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 5 | Common | Common Stock | 2025-06-11 | S | D | 11,495 | $63.47 | 45,080 | I By The 2:22 DNA Trust | — | — | (F7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.08 to $64.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 6 | Common | Common Stock | 2025-06-10 | S | D | 18,412 | $64.02 | 66,089 | I By The 2:22 DNA Trust | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.56 to $64.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 7 | Common | Common Stock | 2025-06-10 | A | A | 1,538 | $0.00 | 8,403 | D By The 2:22 DNA Trust | — | — | |
| 8 | Common | Common Stock | 2025-06-11 | S | D | 7,788 | $62.59 | 56,575 | I By The 2:22 DNA Trust | — | — | (F6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.08 to $63.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 9 | Common | Common Stock | 2025-06-10 | S | D | 1,726 | $64.67 | 64,363 | I By The 2:22 DNA Trust | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.56 to $64.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 10 | Derivative | Stock Option (Right to Buy) | 2025-06-10 | A | A | 2,771 | $0.00 | 2,771 | D | $64.23 · — to 2035-06-09 | 2,771 Common Stock | (F11) The Stock Option was granted on June 10, 2025 and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. |